ReviewFrontiers in cellular and infection microbiology2026
The microbiome-gut-brain axis: a new perspective on the pathogenesis and intervention of frailty.
Review in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With the acceleration of global aging, frailty syndrome has become an important public health challenge. This article reviews the new perspective of the microbiome-gut-brain axis (MGBA) in the pathogenesis and intervention strategies of frailty, and systematically analyzes the bidirectional association between the gut microbiome and frailty, the potential biological mechanisms, and the therapeutic progress targeting the microbiome. Evidence shows that microbiome-gut-brain axis (MGBA) plays a pivotal role in frailty, and its regulation not only helps to reveal the multidimensional nature of frailty, but also provides important directions for the development of novel biomarkers and personalized interventions. Multi-dimensional targeting of MGBA may be an effective way to promote healthy aging.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.